Maturamap - AI assisted therapeutic antibody design
| Reference number | |
| Coordinator | AAX Biotech AB |
| Funding from Vinnova | SEK 450 000 |
| Project duration | November 2024 - May 2026 |
| Status | Completed |
| Venture | MSCA Employment |
| Call | Attract, integrate and retain international excellence 2024 ht |
Important results from the project
Yes, the project met the objective set from the start. It was shown that Seqitope data can improve AI models, and the work also resulted in a more automated wet lab process that increased capacity and efficiency. In addition, the project led to new collaborations and a continued effort through a new Vinnova proposal (2026-00145), which creates good conditions for further development.
Expected long term effects
The project is expected to enable faster and more accurate development of antibody drugs through AI-based decision support. By moving important decisions earlier in the process, costs and risk can be reduced. At the same time, a scalable technology platform is established that strengthens continued innovation and collaboration within Swedish life science.
Approach and implementation
The project was implemented according to plan, focusing on three main parts: validation of AI benefits, scaling up experimental capacity, and development of an analysis pipeline. The activities proved to be well-chosen and could be implemented according to schedule without major deviations. No critical external obstacles arose and collaborations, including with external partners, worked well and contributed to the success of the project.